Skip to main content
SpringerLink
Log in
Book cover

Development of Antibody-Based Therapeutics pp 183–240Cite as

Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology

  • Chapter
  • First Online:

  • 2448 Accesses

Abstract

In this chapter the preclinical considerations for antibody target discovery, validation, and in vitro and in vivo pharmacology will be discussed. A deep understanding of both the biology and the pathology of disease is essential for target identification and validation. This knowledge enables the rationale design of antibody therapeutic attributes including mechanism of action (MOA), specificity, potency, isotype subclass, affinity, and half-life. Subsequently, consideration and utilization of the appropriate animal models will enable optimal translation to the clinic and assist in clinical trial design. Additionally, preclinical considerations for the successful HER2 and CD20 antibody drug therapeutics will be presented as case studies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Notes

  1. 1.

    For this chapter, gene names will be italicized, e.g.,HER2, while the use of gene name or an accepted protein name without italics or other qualifier, will refer to the gene product, the HER2 protein.

References

  • Aalberse RC, Schuurman J, van Ree R (1999) The apparent monovalency of human IgG4 is due to bispecificity. Int Arch Allergy Immunol 118:187–189

    Article  PubMed  CAS  Google Scholar 

  • Albanell J, Codony J, Rovira A et al (2003) Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532:253–268

    Article  PubMed  CAS  Google Scholar 

  • Anderson DR, Grillo-Lopez A, Varns C et al (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. Biochem Soc Trans 25:705–708

    PubMed  CAS  Google Scholar 

  • Angal S, King DJ, Bodmer MW et al (1993) A singel amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 30:105–108

    Article  PubMed  CAS  Google Scholar 

  • Ansell SM (2011) Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. Expert Opin Investig Drugs 20:99–105

    Article  PubMed  CAS  Google Scholar 

  • Barbosa MD, Celis E (2007) Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Drug Discov Today 12:674–681

    Article  PubMed  CAS  Google Scholar 

  • Bargmann CI, Hung MC, Weinberg RA (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649–657

    Article  PubMed  CAS  Google Scholar 

  • Beers SA, Chan CH, James S, French RR et al (2008) Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112:4170–4177

    Article  PubMed  CAS  Google Scholar 

  • Bell DW (2010) Our changing view of the genomic landscape of cancer. J Pathol 220:231–243

    PubMed  CAS  Google Scholar 

  • Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40:852–857

    Article  PubMed  CAS  Google Scholar 

  • Bibeau F, Lopez-Crapez E, Di Fiore F et al (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122–1129

    Article  PubMed  CAS  Google Scholar 

  • Biswas P, Delfanti F, Bernasconi S, Mengozzi M et al (1998) Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 91:258–265

    PubMed  CAS  Google Scholar 

  • Bloom JW, Madanat S, Marriott D et al (1997) Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci 6:407–415

    Article  PubMed  CAS  Google Scholar 

  • Boven E, Winograd B, Berger DP et al (1992) Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 52:5940–5947

    PubMed  CAS  Google Scholar 

  • Brusic V, Bajic VB, Petrovsky N (2004) Computational methods for prediction of T-cell epitopes–a framework for modelling, testing, and applications. Methods 34:436–443

    Article  PubMed  CAS  Google Scholar 

  • Bubien JK, Zhou LJ, Bell PD et al (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2 + conductance found constitutively in B lymphocytes. J Cell Biol 121:1121–1132

    Article  PubMed  CAS  Google Scholar 

  • Buettner M, Meyer B, Schreck S et al (2007) Expression of RANTES and MCP-1 in epithelial cells is regulated via LMP1 and CD40. Int J Cancer 121:2703–2710

    Article  PubMed  CAS  Google Scholar 

  • Burris HA 3rd, Rugo HS, Vukelja SJ et al (2010) Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy. J Clin Oncol 29:5865

    Google Scholar 

  • Carter P, Presta L, Gorman CM et al (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285–4289

    Article  PubMed  CAS  Google Scholar 

  • Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754–758

    Article  PubMed  CAS  Google Scholar 

  • Cartron G, Watier H, Golay J et al (2004) From the bench to bedside: ways to improve rituximab efficacy. Blood 104: 2632–2642

    Article  CAS  Google Scholar 

  • Chan HT, Hughes D, French RR et al (2003) CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 63:5480–5489

    PubMed  CAS  Google Scholar 

  • Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41:98–107

    Article  PubMed  CAS  Google Scholar 

  • Chazin VR, Kaleko M, Miller AD et al (1992) Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7:1859–1866

    PubMed  CAS  Google Scholar 

  • Chien KR (2000) Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol 27:9–14 discussion 92–100

    PubMed  CAS  Google Scholar 

  • Clark EA, Shu G, Ledbetter JA (1985) Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci U S A 82:1766–1770

    Article  PubMed  CAS  Google Scholar 

  • Crone SA, Zhao YY, Fan L et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459–465

    Article  PubMed  CAS  Google Scholar 

  • Damia G, D’Incalci M (2009) Contemporary pre-clinical development of anticancer agents–what are the optimal preclinical models? Eur J Cancer 45:2768–2781

    Article  PubMed  CAS  Google Scholar 

  • De Both NJ, Vermey M, Groen N et al (1997) Clonal growth of colorectal-carcinoma cell lines transplanted to nude mice. Int J Cancer 72:1137–1141

    Article  PubMed  Google Scholar 

  • De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28:482–490

    Article  PubMed  CAS  Google Scholar 

  • de Jong M, Maina T (2010) Of mice and humans: are they the same?–Implications in cancer translational research. J Nucl Med 51:501–504

    Article  PubMed  Google Scholar 

  • Ding L, Getz G, Wheeler DA et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075

    Article  PubMed  CAS  Google Scholar 

  • Doronina SO, Toki BE, Torgov MY et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778–784

    Article  PubMed  CAS  Google Scholar 

  • Eccles SA (ed) (2002) Models for evaluation of targeted therapies of metastatic disease. Humana Press, Totowa, pp. 293–331

    Google Scholar 

  • Farag SS, Flinn IW, Modali R et al (2004) Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103:1472–1474

    Article  PubMed  CAS  Google Scholar 

  • Fendly BM, Winget M, Hudziak RM et al (1990) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550–1558

    PubMed  CAS  Google Scholar 

  • Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611

    Article  PubMed  CAS  Google Scholar 

  • Fiebig HH, Maier A, Burger AM (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40:802–820

    Article  PubMed  CAS  Google Scholar 

  • Firestone B (2010) The challenge of selecting the ‘right’ in vivo oncology pharmacology model. Curr Opin Pharmacol 10:391–396

    Article  PubMed  CAS  Google Scholar 

  • Frese KK, Tuveson DA (2007) Maximizing mouse cancer models. Nat Rev Cancer 7:645–658

    Article  PubMed  CAS  Google Scholar 

  • Garber K (2009) From human to mouse and back: tumorgraft models surge in popularity. J Natl Cancer Inst 101:6–8

    PubMed  Google Scholar 

  • Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671–680

    PubMed  CAS  Google Scholar 

  • Goldstein NI, Prewett M, Zuklys K et al (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311–1318

    PubMed  CAS  Google Scholar 

  • Grant SL, Hammacher A, Douglas AM et al (2002) An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene 21:460–474

    Article  PubMed  CAS  Google Scholar 

  • Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158

    Article  PubMed  CAS  Google Scholar 

  • Grosso AR, Martins S, Carmo-Fonseca M (2008) The emerging role of splicing factors in cancer. EMBO Rep 9:1087–1093

    Article  PubMed  CAS  Google Scholar 

  • Guglin M, Cutro R, Mishkin JD (2008) Trastuzumab-induced cardiomyopathy. J Card Fail 14:437–444

    Article  PubMed  CAS  Google Scholar 

  • Guy CT, Webster MA, Schaller M et al (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89:10578–10582

    Article  PubMed  CAS  Google Scholar 

  • Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  PubMed  CAS  Google Scholar 

  • Hansen K, Khanna C (2004) Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 40:858–880

    Article  PubMed  CAS  Google Scholar 

  • Hembruff SL, Cheng N (2009) Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. Cancer Ther 7:254–267

    PubMed  CAS  Google Scholar 

  • Hewitt SM (2009) Tissue microarrays as a tool in the discovery and validation of tumor markers. Methods Mol Biol 520:151–161

    Article  PubMed  CAS  Google Scholar 

  • Hoeben A, Landuyt B, Highley MS et al (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549–580

    Article  PubMed  CAS  Google Scholar 

  • Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393–11398

    Article  PubMed  CAS  Google Scholar 

  • Hudziak RM, Lewis GD, Winget M et al (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165–1172

    PubMed  CAS  Google Scholar 

  • Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 84:7159–7163

    Article  PubMed  CAS  Google Scholar 

  • Jones JT, Akita RW, Sliwkowski MX (1999) Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447:227–231

    Article  PubMed  CAS  Google Scholar 

  • Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806

    Article  PubMed  CAS  Google Scholar 

  • Junttila TT, Parsons K, Olsson C et al (2010) Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 70:4481–4489

    Article  PubMed  CAS  Google Scholar 

  • Kalnina Z, Zayakin P, Silina K et al (2005) Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42:342–357

    Article  PubMed  CAS  Google Scholar 

  • Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820–827

    Article  PubMed  CAS  Google Scholar 

  • Kelland LR (2004) Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40:827–836

    Article  PubMed  CAS  Google Scholar 

  • Kim DH, Jung HD, Kim JG et al (2006) FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108:2720–2725

    Article  PubMed  CAS  Google Scholar 

  • Kim ES, Khuri FR, Herbst RS (2001) Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13:506–513

    Article  PubMed  CAS  Google Scholar 

  • Klein PM, Dybdal N (2003) Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol 30:49–53

    Article  PubMed  CAS  Google Scholar 

  • Koivunen J, Aaltonen V, Peltonen J (2006) Protein kinase C (PKC) family in cancer progression. Cancer Lett 235:1–10

    Article  PubMed  CAS  Google Scholar 

  • Koren E, De Groot AS, Jawa V et al (2007) Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124:26–32

    Article  PubMed  CAS  Google Scholar 

  • Kumar R, Shepard HM, Mendelsohn J (1991) Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol 11:979–986

    PubMed  CAS  Google Scholar 

  • Labrijn AF, Buijsse AO, van den Bremer ET et al (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 27:767–771

    Article  PubMed  CAS  Google Scholar 

  • Lazar GA, Dang W, Karki S et al (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103:4005–4010

    Article  PubMed  CAS  Google Scholar 

  • Le Y, Zhou Y, Iribarren P, Wang J (2004) Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 1:95–104

    PubMed  CAS  Google Scholar 

  • Lee KF, Simon H, Chen H et al (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394–398

    Article  PubMed  CAS  Google Scholar 

  • Lewis GD, Figari I, Fendly B et al (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255–263

    Article  PubMed  CAS  Google Scholar 

  • Lewis Phillips GD, Li G, Dugger DL et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280–9290

    Article  PubMed  CAS  Google Scholar 

  • Liang Y, Buckley TR, Tu L et al (2001) Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics 53:357–368

    Article  PubMed  CAS  Google Scholar 

  • Loisel S, Ohresser M, Pallardy M et al (2007) Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 62:34–42

    Article  PubMed  Google Scholar 

  • Luo B, Cheung HW, Subramanian A et al (2008) Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A 105:20380–20385

    Article  PubMed  CAS  Google Scholar 

  • Luo J, Emanuele MJ, Li D et al (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835–848

    Article  PubMed  CAS  Google Scholar 

  • Lynch DH, Yang XD (2002) Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 29:47–50

    Article  PubMed  CAS  Google Scholar 

  • Manfredi MG, Ecsedy JA, Meetze KA et al (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 104:4106–4111

    Article  PubMed  CAS  Google Scholar 

  • Masuda K, Kubota T, Kaneko E et al (2007) Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 44:3122–3131

    Article  PubMed  CAS  Google Scholar 

  • McMurry JA, Gregory SH, Moise L et al (2007) Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 25:3179–3191

    Article  PubMed  CAS  Google Scholar 

  • Miao HQ, Hu K, Jimenez X, Navarro E et al (2006) Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun 345:438–445

    Article  PubMed  CAS  Google Scholar 

  • Millauer B, Wizigmann-Voos S, Schnurch H et al (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835–846

    Article  PubMed  CAS  Google Scholar 

  • Mishima K, Johns TG, Luwor RB et al (2001) Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61:5349–5354

    PubMed  CAS  Google Scholar 

  • Moffat J, Grueneberg DA, Yang X et al (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124:1283–1298

    Article  PubMed  CAS  Google Scholar 

  • Morell A, Terry WD, Waldmann TA (1970) Metabolic properties of igg subclasses in man. J Clin Invest 49:673–680

    Article  PubMed  CAS  Google Scholar 

  • Monteclaro FS, Charo IF (1997) The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. J Biol Chem 272:23186–23190

    Article  PubMed  CAS  Google Scholar 

  • Mossner E, Brunker P, Moser S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393–4402

    Article  PubMed  CAS  Google Scholar 

  • Muller WJ, Sinn E, Pattengale PK et al (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115

    Article  PubMed  CAS  Google Scholar 

  • Muller YA, Chen Y, Christinger HW et al (1998) VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6:1153–1167

    Article  PubMed  CAS  Google Scholar 

  • Musolino A, Naldi N, Bortesi B et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789–1796

    Article  PubMed  CAS  Google Scholar 

  • Nahta R, Yu D, Hung MC et al (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–280

    Article  PubMed  CAS  Google Scholar 

  • Nahta R, Yuan LX, Zhang B et al (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118–11128

    Article  PubMed  CAS  Google Scholar 

  • Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068

    Article  CAS  Google Scholar 

  • Niwa R, Hatanaka S, Shoji-Hosaka E et al (2004) Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 10:6248–6255

    Article  PubMed  CAS  Google Scholar 

  • Ohbo K, Suda T, Hashiyama M et al (1996) Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 87:956–967

    PubMed  CAS  Google Scholar 

  • O’Keefe TL, Williams GT, Davies SL, Neuberger MS (1998) Mice carrying a CD20 gene disruption. Immunogenetics 48:125–132

    Article  PubMed  Google Scholar 

  • Pan Q, Chanthery Y, Liang WC et al (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11:53–67

    Article  PubMed  CAS  Google Scholar 

  • Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812

    Article  PubMed  CAS  Google Scholar 

  • Pegram M, Ngo D (2006) Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. Adv Drug Deliv Rev 58:723–734

    Article  PubMed  CAS  Google Scholar 

  • Pietras RJ, Fendly BM, Chazin VR et al (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829–1838

    PubMed  CAS  Google Scholar 

  • Pio R, Blanco D, Pajares MJ et al (2010) Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. BMC Genomics 11:352

    Article  PubMed  CAS  Google Scholar 

  • Plosker GL, Keam SJ (2006) Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66:449–475

    Article  PubMed  CAS  Google Scholar 

  • Qayum N, Muschel RJ, Im JH et al (2009) Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 69:6347–6354

    Article  PubMed  CAS  Google Scholar 

  • Quinn TP, Peters KG, De Vries C et al (1993) Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A 90:7533–7537

    Article  PubMed  CAS  Google Scholar 

  • Quon K, Kassner PD (2009) RNA interference screening for the discovery of oncology targets. Expert Opin Ther Targets 13:1027–1035

    Article  PubMed  CAS  Google Scholar 

  • Racila E, Racila DM, Ritchie JM et al (2006) The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics 58:1–8

    Article  PubMed  CAS  Google Scholar 

  • Racila E, Link BK, Weng WK et al (2008) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 14:6697–6703

    Article  PubMed  CAS  Google Scholar 

  • Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    PubMed  CAS  Google Scholar 

  • Ritter CA, Perez-Torres M, Rinehart C et al (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909–4919

    Article  PubMed  CAS  Google Scholar 

  • Robak T, Roak E (2011) New Anti-CD20 monocolonal antibodies for the treatment of B-Cell lymphoid malignancies. Biodrugs 25:13–25

    Article  PubMed  CAS  Google Scholar 

  • Sarup JC, Johnson RM, King KL et al (1991) Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1:72–82

    PubMed  CAS  Google Scholar 

  • Schechter AL, Stern DF, Vaidyanathan L et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516

    Article  PubMed  CAS  Google Scholar 

  • Schmiedel J, Blaukat A, Li S et al (2008) Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13:365–373

    Article  PubMed  CAS  Google Scholar 

  • Schuurman J, Perdok GJ, Gorter AD et al (2001) The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 38:1–8

    Article  PubMed  CAS  Google Scholar 

  • Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215–1221

    Article  PubMed  CAS  Google Scholar 

  • Seinen E, Burgerhof JG, Jansen RC et al (2010) RNAi experiments in D. melanogaster: solutions to the overlooked problem of off-targets shared by independent dsRNAs. PLoS ONE 5:13119

    Article  CAS  Google Scholar 

  • Selvey S, Thompson EW, Matthaei K et al (2001) Beta-actin–an unsuitable internal control for RT-PCR. Mol Cell Probes 15:307–311

    Article  PubMed  CAS  Google Scholar 

  • Semba T, Funahashi Y, Ono N et al (2004) An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. Clin Cancer Res 10:1430–1438

    Article  PubMed  CAS  Google Scholar 

  • Shalaby MR, Carter P, Maneval D et al (1995) Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. Clin Immunol Immunopathol 74:185–192

    Article  PubMed  CAS  Google Scholar 

  • Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644–1652

    PubMed  CAS  Google Scholar 

  • Shepard HM, Jin P, Slamon DJ et al (2008) Herceptin Handbook. Exp Pharmacol 181:183–219

    Article  CAS  Google Scholar 

  • Shields RL, Namenuk AK, Hong K et al (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591–6604

    Article  PubMed  CAS  Google Scholar 

  • Shih C, Padhy LC, Murray M et al (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290:261–264

    Article  PubMed  CAS  Google Scholar 

  • Shultz LD, Lyons BL, Burzenski LM et al (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174:6477–6489

    PubMed  CAS  Google Scholar 

  • Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7:118–130

    Article  PubMed  CAS  Google Scholar 

  • Sigoillot FD, King RW (2010) Vigilance and validation: keys to success in RNAi screening. ACS Chem Biol 6:47–60

    Article  PubMed  CAS  Google Scholar 

  • Silva JM, Marran K, Parker JS et al (2008) Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319:617–620

    Article  PubMed  CAS  Google Scholar 

  • Simon R (2010) Applications of tissue microarray technology. Methods Mol Biol 664:1–16

    Article  PubMed  CAS  Google Scholar 

  • Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  • Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22:7359–7368

    Article  PubMed  CAS  Google Scholar 

  • Solanas M, Moral R, Escrich E (2001) Unsuitability of using ribosomal RNA as loading control for Northern blot analyses related to the imbalance between messenger and ribosomal RNA content in rat mammary tumors. Anal Biochem 288:99–102

    Article  PubMed  CAS  Google Scholar 

  • Staroselsky AN, Radinsky R, Fidler IJ et al (1992) The use of molecular genetic markers to demonstrate the effect of organ environment on clonal dominance in a human renal-cell carcinoma grown in nude mice. Int J Cancer 51:130–138

    Article  PubMed  CAS  Google Scholar 

  • Steel GG, Courtenay VD, Peckham MJ (1983) The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer 47:1–13

    Article  PubMed  CAS  Google Scholar 

  • Steere AC, Klitz W, Drouin EE et al (2006) Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 203:961–971

    Article  PubMed  CAS  Google Scholar 

  • Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458:719–724

    Article  PubMed  CAS  Google Scholar 

  • Sultan M, Schulz MH, Richard H, Magen A et al (2008) A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321:956–960

    Article  PubMed  CAS  Google Scholar 

  • Suter TM, Cook-Bruns N, Barton C (2004) Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13:173–183

    Article  PubMed  CAS  Google Scholar 

  • Tamura K, Shimizu C, Hojo T et al (2011). FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 22(6):1302–1307

    Article  PubMed  CAS  Google Scholar 

  • Tang Y, Lou J, Alpaugh RK et al (2007) Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 179:2815–2823

    PubMed  CAS  Google Scholar 

  • Tatarewicz SM, Wei X, Gupta S et al (2007) Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson’s disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 27:620–627

    Article  PubMed  Google Scholar 

  • Tedder TF, Boyd AW, Freedman AS et al (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135:973–979

    PubMed  CAS  Google Scholar 

  • Tedder TF, Penta A (1989) Structure of the CD20 antigen and gene of human and mouse B-cells: use of transfected cell lines to examine the workshop panel of antibodies. In: Knapp W, Dorken B, Gilks WR, et al. (eds) Leukocyte Antigens. Oxford University Press, Oxford pp 48–50

    Google Scholar 

  • Tedder TF, Baras A, Xiu Y (2006) Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 28:351–364

    Article  PubMed  CAS  Google Scholar 

  • Teeling JL, Mackus WJM, Wiegman LJJM et al (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362–371

    PubMed  CAS  Google Scholar 

  • Tennstedt P, Sauter G (2010) Quality aspects of TMA analysis. Methods Mol Biol 664:17–26

    Article  PubMed  CAS  Google Scholar 

  • Terman BI, Dougher-Vermazen M, Carrion ME et al (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579–1586

    Article  PubMed  CAS  Google Scholar 

  • Uchida J, Lee Y, Hasegawa M, Liang Y et al (2004) Mouse CD20 expression and function. Int Immunol 16:119–129

    Article  PubMed  CAS  Google Scholar 

  • Vandesompele J, De Preter K, Pattyn F, et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034

    Google Scholar 

  • Velculescu VE (2008) Defining the blueprint of the cancer genome. Carcinogenesis 29:1087–1091

    Article  PubMed  CAS  Google Scholar 

  • Venables JP (2006) Unbalanced alternative splicing and its significance in cancer. BioEssays 28:378–386

    Article  PubMed  CAS  Google Scholar 

  • Viola A, Luster AD (2008) Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48:171–197

    Article  PubMed  CAS  Google Scholar 

  • von Hoff D (2010). The last 12 weeks. 2010 David A. Karnofsky memorial award from the American Society of Clinical Oncology

    Google Scholar 

  • Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9:4227–4239

    PubMed  Google Scholar 

  • Walker JR, Singal PK, Jassal DS (2009) The art of healing broken hearts in breast cancer patients: trastuzumab and heart failure. Exp Clin Cardiol 14:e62–67

    PubMed  CAS  Google Scholar 

  • Wang ET, Sandberg R, Luo S, Khrebtukova I et al (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456:470–476

    Article  PubMed  CAS  Google Scholar 

  • Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947

    Article  PubMed  CAS  Google Scholar 

  • Westbrook TF, Stegmeier F, Elledge SJ (2005) Dissecting cancer pathways and vulnerabilities with RNAi. Cold Spring Harb Symp Quant Biol 70:435–444

    Article  PubMed  CAS  Google Scholar 

  • Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113

    Article  PubMed  CAS  Google Scholar 

  • Wu Y, Hooper AT, Zhong Z et al (2006a) The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 119:1519–1529

    Article  PubMed  CAS  Google Scholar 

  • Wu Y, Zhong Z, Huber J et al (2006b) Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 12:6573–6584

    Article  PubMed  CAS  Google Scholar 

  • Yang XD, Jia XC, Corvalan JR et al (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17–23

    Article  PubMed  CAS  Google Scholar 

  • Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821

    Article  PubMed  CAS  Google Scholar 

  • Zhang Q, Wang P, Kim Y et al (2008) Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res 36:W513–518

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Gordon M, Schultheis AM et al (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25:3712–3718

    Article  PubMed  CAS  Google Scholar 

  • Zhu G, Chang Y, Zuo J et al (2001) Fudenine, a C-terminal truncated rat homologue of mouse prominin, is blood glucose-regulated and can up-regulate the expression of GAPDH. Biochem Biophys Res Commun 281:951–956

    Article  PubMed  CAS  Google Scholar 

  • Zhu Z, Hattori K, Zhang H et al (2003) Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17:604–611

    Article  PubMed  CAS  Google Scholar 

  • Zuccolo J, Bau J, Childs SJ et al (2010) Phylogenetic analysis of the MS4A and TMEM176 gene families. PLoS ONE 5:e9369

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biological Sciences, Takeda California, 285 East Grand Avenue, South San Francisco, CA, 94080, USA

    Gregory Landes

  2. Experimental Medicine, Takeda California, 285 East Grand Avenue, South San Francisco, CA, 94080, USA

    Kathleen Elias

Authors
  1. Gregory Landes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen Elias
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory Landes .

Editor information

Editors and Affiliations

  1. Merck Research Laboratory, Merck & CO Inc., California Avenue 901, Palo Alto, 94304, California, USA

    Mohammad A. Tabrizi

  2. Pfizer CTI- New York, East 29th Street 450, New York, 10016, New York, USA

    Gadi G. Bornstein

  3. Takeda California, Inc., E. Grand Avenue 285, South San Francisco, 94080, California, USA

    Scott L. Klakamp

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Landes, G., Elias, K. (2012). Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology. In: Tabrizi, M., Bornstein, G., Klakamp, S. (eds) Development of Antibody-Based Therapeutics. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5955-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-5955-3_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-5953-9

  • Online ISBN: 978-1-4419-5955-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation